N-((1s,4s)-4-((4-(dimethylamino)-6-methylpyrimidin-2-yl)amino)cyclohexyl)-3,5-bis(trifluoromethyl)benzamide | 773143-06-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-((1s,4s)-4-((4-(dimethylamino)-6-methylpyrimidin-2-yl)amino)cyclohexyl)-3,5-bis(trifluoromethyl)benzamide
• CAS: 773143-06-9
• 化学式: C₂₂H₂₅F₆N₅O
• 分子量: 489.464
• InChiKey: YHSRTUXPXLVIAG-CALCHBBNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.04
• 重原子数：
  34.0
• 可旋转键数：
  5.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  70.15
• 氢给体数：
  2.0
• 氢受体数：
  5.0

反应信息

• 作为产物：
  描述：

  cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-4-aminocyclohexane 、 3,5-双三氟甲基苯甲酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-((1s,4s)-4-((4-(dimethylamino)-6-methylpyrimidin-2-yl)amino)cyclohexyl)-3,5-bis(trifluoromethyl)benzamide
  参考文献：
  名称：

  Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: In vitro profiling and in vivo evaluation

  摘要：

  A series of pyrimidine analogues derived from ATC0175 were potent antagonists of human MCH-R1 in vitro. Significantly improved receptor selectivity was achieved with several analogues from this series, but no improvement in brain partitioning was noted. One example from this series was shown to inhibit food intake and decrease body weight in a chronic study. However no clear correlation between the pharmacodynamic effect and the pharmacokinetic data with respect to brain concentration was discernible leading us to conclude that the observed effect was most likely not due to interaction with the MCH-R1. (c) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.09.003

文献信息

• Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
  申请人：Sekiguchi Yoshinori

  公开号：US20050197350A1

  公开（公告）日：2005-09-08

  The present invention relates to novel compounds of the Formula (I): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涉及一种新的化合物，其化学式为(I)，该化合物作为MCH受体拮抗剂。这些组合物在制药组合物中的应用包括预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖症、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗死、暴食症包括贪食症、厌食症、精神障碍包括躁郁症、精神分裂症、谵妄、痴呆、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍包括帕金森病、癫痫和成瘾等。
• QUINOLINE, TETRAHYDROQUINOLINE AND PYRIMIDINE DERIVATIVES AS MCH ANTAGONIST
  申请人：Taisho Pharmaceutical Co. Ltd.

  公开号：EP1464335A2

  公开（公告）日：2004-10-06

  The present invention relates to compounds of the Formula (I) wherein Q is: which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涉及式（I）化合物 其中 Q 为 作为 MCH 受体拮抗剂的化合物。这些组合物可用于药物组合物中，其用途包括预防或治疗改善记忆功能、睡眠和唤醒、焦虑、抑郁、情绪障碍、癫痫发作、肥胖、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗塞、暴饮暴食症（包括贪食症）、厌食症、心肌梗塞、暴食症（包括贪食症）、厌食症、精神障碍（包括躁狂抑郁症）、精神分裂症、谵妄、痴呆、压力、认知障碍、注意力缺陷障碍、药物滥用障碍和运动障碍（包括帕金森病）、癫痫和成瘾。
• [EN] NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF<br/>[FR] NOUVEAUX DERIVES QUINOLINE, TETRAHYDROQUINAZOLINE ET PYRIMIDINE, PROCEDES DE TRAITEMENT EN LIAISON AVEC L'UTILISATION DE CES DERNIERS
  申请人：TAISHO PHARMA CO LTD

  公开号：WO2004087669A1

  公开（公告）日：2004-10-14

  The present invention relates to novel compounds of the Formula (I): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.
• Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: In vitro profiling and in vivo evaluation
  作者：Graeme Semple、Thuy-Anh Tran、Bryan Kramer、Debbie Hsu、Sangdon Han、Juyi Choi、Pureza Vallar、Martin D. Casper、Ning Zou、Erin K. Hauser、William Thomsen、Kevin Whelan、Dipanjan Sengupta、Michael Morgan、Yoshinori Sekiguchi、Kosuke Kanuma、Shigeyuki Chaki、Andrew J. Grottick

  DOI：10.1016/j.bmcl.2009.09.003

  日期：2009.11

  A series of pyrimidine analogues derived from ATC0175 were potent antagonists of human MCH-R1 in vitro. Significantly improved receptor selectivity was achieved with several analogues from this series, but no improvement in brain partitioning was noted. One example from this series was shown to inhibit food intake and decrease body weight in a chronic study. However no clear correlation between the pharmacodynamic effect and the pharmacokinetic data with respect to brain concentration was discernible leading us to conclude that the observed effect was most likely not due to interaction with the MCH-R1. (c) 2009 Elsevier Ltd. All rights reserved.